HC Wainwright Forecasts Armata Pharmaceuticals Q1 Earnings

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Armata Pharmaceuticals in a report released on Friday, March 21st. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.50) EPS and Q4 2025 earnings at ($0.67) EPS.

Armata Pharmaceuticals Trading Down 8.7 %

Shares of ARMP stock opened at $1.68 on Monday. The stock has a market capitalization of $60.78 million, a PE ratio of -1.02 and a beta of 0.87. Armata Pharmaceuticals has a 52-week low of $1.63 and a 52-week high of $4.25.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.